Clinical considerations for the management of androgen indifferent prostate cancer.

ABSTRACT:

Background

Many systemic therapies for advanced prostate cancer work by disrupting androgen receptor signaling. Androgen indifferent prostate cancer (AIPC) variants, including aggressive variant prostate cancer (AVPC), neuroendocrine prostate cancer (NEPC), and double-negative prostate cancer (DNPC), are increasingly common and often overlapping resistance phenotypes following treatment with androgen receptor signaling inhibitors in men with metastatic castration-resistant prostate cancer and are associated with poor outcomes. Understanding the underlying biology and identifying effective therapies for AIPC is paramount for improving survival for men with prostate cancer.

Methods

In this review, we summarize the current knowledge on AIPC variants, including our current under

SUBMITTER: Berchuck JE 

PROVIDER: S-EPMC8353003 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature